• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Upexi Revenue Increases 144% Year-Over-Year and 53.5% Sequentially to $27.3 Million for Fiscal First Quarter 2024

    11/20/23 4:05:00 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $UPXI alert in real time by email

    TAMPA, FL / ACCESSWIRE / November 20, 2023 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct to Consumer brand owner and innovator in aggregation, today announced its financial results for the fiscal first quarter 2024 ending September 30, 2023.

    "Revenue for our fiscal first quarter 2024 grew 144% year-over-year and 53.5% sequentially driven by growth in both branded products and re-commerce," commented CEO of Upexi, Allan Marshall. "While our cost cutting measures are now beginning to yield material year-over-year decreases in operating expenses as a percentage of revenue, we have also continued to invest significantly in the future growth of our brands."

    Fiscal First Quarter 2024 Financial Highlights:

    • Revenue totaled $27.3 million, an increase of 144% year-over-year and 53.5% sequentially.
    • Re-commerce revenue, 76% of total revenue, increased 187% and branded product revenue, 24% of total revenue, increased 65.3% year-over-year.
    • Gross profit totaled $8.7 million, an increase of 49.7%, as compared to $5.8 million for the same period the prior year.
    • Sales and marketing expense totaled $2.9 million, an increase of 65%, as compared to $1.7 million the prior year.
    • General and administrative expenses totaled $2.3 million or 8.2% of revenue, an increase of 6%, as compared to $2.1 million or 19% of revenue, for the same period the prior year.
    • Adjusted EBITDA was approximately $750 thousand as compared to an Adjusted EBITDA loss of approximately $525 thousand the prior year, approximately a $1.28 million improvement year-over-year.
    • Net loss attributable to Upexi, Inc. shareholders was $1.35 million, or $0.07 per basic and diluted share, as compared to a net loss of approximately $2.6 million, or $0.16 per basic and diluted share, for the same period last year.
    • Shareholder equity was $27.5 million as of September 30, 2023.
    • Cash and cash equivalents totaled $417 thousand as of September 30, 2023, and availability on the line of credit was $6.2 million.

    Fiscal First Quarter 2024 and Subsequent Operational Highlights

    • Children's toy brand, Tytan Tiles, launched its first licensed Disney Frozen Product on Amazon through its partnership with The Walt Disney Company.
    • In the first month of launch on Amazon, Tytan Tiles is on a run rate to move 115 units per day and increased its rank on Amazon from 20,000 to 4,000.
    • Disney Frozen product line is the first of several Disney products expected to be launched.
    • Pet care brand, Lucky Tail, launched expansion of product line to include all-natural dog supplements offered via subscription and in bundles.
    • Vitamedica acne treatment is expecting data from its study in early 2024.
    • High-volume re-commerce provider of branded OTC products, Cygnet Online, increased revenue sequentially by approximately $1.5 million, with gross profit margins increasing from 44% to 48%.

    Financial Highlights for the Fiscal First Quarter 2024

    Revenue totaled $27.4 million, an increase of $16.1 million or 144% as compared to $11.2 million for the same period the prior year. Revenue increased 53.4% sequentially as compared to $17.8 million in fiscal Q4 of 2023. Revenue growth was primarily due to an increase in re-commerce revenue of 187% and branded product revenue of 24% year-over-year. The Company's strategy will continue to focus on the growth of our brands organically and through expansion into additional international markets.

    Cost of revenue totaled $18.6 million, an increase of 245% as compared to $5.8 million for the same period the prior year. The cost of revenue increase was primarily related to the acquisition of Neti and the re-commerce business. Gross profit increased by approximately $2.9 million compared to the prior year. The combined re-commerce segment only increased approximately $800 thousand while the branded products increased gross profit by over $2.1 million.

    Sales and marketing expenses were approximately $2.9 million, an increase of 65% compared to approximately $1.7 million for the same period the prior year. As a percentage of revenue, sales and marketing expenses were 10.4% for fiscal Q1 2024 as compared to 15.4% for fiscal Q1 2023. The increase in sales and marketing expenses was primarily related to the focus on the branded product revenue growth and strategic marketing to maximize the return on long-term recurring customer growth.

    Distribution costs increased $723 thousand or 34% compared with the same period the prior year primarily due to the overall growth of revenue. Management has implemented several consolidation, repackaging and pricing strategies to continue to reduce the overall distribution costs of product sales. Management expects the implementation of its initial strategies to be completed by March of 2024.

    General and administrative expenses totaled $2.3 million or 8.2% of revenue, an increase of 6%, as compared to $2.1 million or 19% of revenue, for the same period the prior year. Management continues to operate the Company efficiently to enable sales growth without significant increases in general and administrative costs.

    Adjusted EBITDA was approximately $750 thousand as compared to an Adjusted EBITDA loss of approximately $525 thousand the prior year, approximately a $1.2 million improvement year-over-year.

    The Company had a net loss from continued operations of $1.35 million as compared to a loss of $2.6 million for the same period the prior year. The decrease in the net loss from continuing operations is primarily related to the above-mentioned changes.

    As of September 30, 2023, the Company had cash of $417 thousand, availability on the line of credit of $6.2 million, and stockholders' equity attributed to Upexi stockholders of approximately $27.5 million.

    As of today, November 20, 2023, there are 20,306,870 shares of common stock outstanding.

    Financial Results Conference Call

    Event:First Quarter 2024 Financial Results Conference Call
    Date:Monday, November 20, 2023
    Time:4:30 p.m. Eastern Time
    Live Call:1-877-300-8521 (U.S. Toll-Free) or 1-412-317-6026 (International)
    Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1641098&tp_key=e91f34a943

    For those unable to join the conference call, a dial-in replay of the call will be available until December 4, 2023 and can be accessed by dialing +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International) and entering replay pin number: 10183924. Additional details are available under the Investor Relations section of the Company's website: https://upexi.com/investors .

    About Upexi, Inc.:

    Upexi is a multi-faceted brand owner with established brands in the health, wellness, pet, beauty and other growing markets. We operate in emerging industries with high growth trends and look to drive organic growth of our current brands. We focus on direct to consumer and Amazon brands that are scalable and have anticipated, high industry growth trends. Our goal is to continue to accumulate consumer data and build out a significant customer database across all industries we sell into. The growth of our current database has been key to the year over year gains in sales and profits. To drive additional growth, we have and will continue to acquire profitable Amazon and eCommerce businesses that can scale quickly and reduce costs through corporate synergies. We utilize our in-house, SaaS programmatic ad technology to help achieve a lower cost per acquisition and accumulate consumer data for increased cross-selling between our growing portfolio of brands.

    FORWARD LOOKING STATEMENTS:

    This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with business strategy, potential acquisitions, revenue guidance, product development, integration and synergies of acquiring companies and personnel. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

    Adjusted EBITDA

    Three Months Ended
    September 30,
    2023 2022
    Net income (Net loss) GAAP
    $(1,356,388) $(2,597,515)
    Interest expense, net
    874,185 433,478
    Depreciation and amortization
    1,472,905 924,406
    Income Tax
    (472,367) (708,201)
    Stock Compensation
    421,887 927,326
    Gain on sale of Interactive Offers
    (380,624.00) -
    Change in derivative liability
    - (1,770)
    Loss from discontinued operations
    193,040 644,615
    Loss attributable to non-controlling interest
    - (148,005)
    $752,638 $(525,666)

    Use of Non-GAAP Financial Measures

    The Company discloses and uses the above-mentioned non-GAAP financial measures internally as a supplement to GAAP financial information to evaluate its operating performance, for financial planning purposes, to establish operational goals, for compensation plans, to measure debt service capability, for capital expenditure planning and to determine working capital needs and believes that these are useful financial measures also used by investors. Non-GAAP adjusted EBITDA is defined as GAAP net income or net loss before interest, taxes, depreciation and amortization (EBITDA) adjusted for the non-cash stock compensation and stock option expense, acquisition, integration & restructuring expenses, charges and gains or losses from extinguishment of debt and other non-cash items. Non-GAAP EBITDA and non-GAAP adjusted EBITDA are not terms defined by GAAP and, as a result, the Company's measure of non-GAAP EBITDA and non-GAAP adjusted EBITDA might not be comparable to similarly titled measures used by other companies. Generally, a non-GAAP financial measure is a numerical measure of a company's performance, financial position, or cash flow that either excludes or includes amounts that are not normally included in the most directly comparable measure calculated and presented in accordance with GAAP. The non-GAAP financial measures discussed above, however, should be considered in addition to, and not as a substitute for, or superior to net income or net loss as reported for GAAP on the Consolidated Statements of Operations, cash and cash flows on the Consolidated Statement of Cash Flows or other measures of financial performance prepared in accordance with GAAP, and as reflected on the Company's financial statements prepared in accordance with GAAP. These non-GAAP financial measures are not a substitute for or presented in lieu of financial measures provided by GAAP and all measures and disclosures of financial information pursuant to GAAP should be read to obtain a comprehensive and thorough understanding of the Company's financial results. The reconciliations of non-GAAP EBITDA and non-GAAP adjusted EBITDA to GAAP operating income (loss) and/or GAAP net income (net loss) referred to in the highlights or elsewhere are provided in the schedules that are a part of this document.

    Company Contact

    Andrew Norstrud, Chief Financial Officer
    Email: [email protected]
    Phone: (702) 332-5591

    Investor Relations Contact

    KCSA Strategic Communications
    Valter Pinto or Jack Perkins
    Email: [email protected]
    Phone: (212) 896-1254

    UPEXI, INC.
    CONDENSED CONSOLDIATED BALANCE SHEETS (UNAUDITED)

    September 30, June 30,
    2023 2023
    ASSETS
    Current assets
    Cash
    $417,108 $4,492,291
    Accounts receivable
    9,756,622 7,163,564
    Inventory
    13,786,262 11,557,128
    Due from Bloomios
    - 845,443
    Prepaid expenses and other receivables
    957,584 1,307,299
    Current assets of discontinued operations
    - 89,989
    Total current assets
    24,917,576 25,455,714
    Property and equipment, net
    7,744,874 7,526,463
    Intangible assets, net
    12,385,139 13,571,960
    Goodwill
    11,719,155 10,251,281
    Deferred tax asset
    6,076,423 5,604,056
    Other assets
    365,060 96,728
    Assets held for sale
    - 936,054
    Right-of-use asset
    2,037,515 410,811
    Total other assets
    40,328,166 38,397,353
    Total assets
    $65,245,742 $63,853,067
    LIABILITIES AND STOCKHOLDERS' EQUITY
    Current liabilities
    Accounts payable
    $4,638,195 $3,969,746
    Accrued compensation
    513,934 533,842
    Deferred revenue
    153,769 -
    Accrued liabilities
    3,883,842 3,365,562
    Acquisition payable
    300,000 -
    Current portion of notes payable
    4,255,357 1,302,021
    Current portion of convertible notes payable
    - 1,254,167
    Current portion of acquisition note payable
    5,656,620 5,656,620
    Current portion of related party note payable
    - 1,429,356
    Line of Credit
    118,001 882,845
    Current portion of operating lease payable
    517,099 419,443
    Current liabilities of discontinued operations
    - 792,408
    Total current liabilities
    20,036,817 19,606,010
    Operating lease payable, net of current portion
    1,600,489 163,359
    Related party note payable
    1,444,493 -
    Convertible notes payable
    2,150,000 895,833
    Acquisition notes payable, net of current
    7,968,497 7,605,085
    Notes payable, net of current portion
    4,475,450 7,746,157
    Total long-term liabilities
    17,638,929 16,410,434
    Commitments and contingencies
    Stockholders' equity
    Preferred stock, $0.001 par value, 100,000,000 shares authorized, and 500,000 and 500,000 shares issued and outstanding, respectively
    500 500
    Common stock, $0.001 par value, 100,000,000 shares authorized, and 20,397,779 and 16,713,345 shares issued and outstanding, respectively
    20,307 20,216
    Additional paid in capital
    52,106,752 51,522,229
    Accumulated deficit
    (24,557,563) (23,201,175)
    Total stockholders' equity attributable to Upexi, Inc.
    27,569,996 28,341,770
    Non-controlling interest in subsidiary
    (505,147)
    Total stockholders' equity
    27,569,996 27,836,623
    Total liabilities and stockholders' equity
    $65,245,742 $63,853,067

    UPEXI, INC.
    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

    Three Month's Ended March 31,
    2021 2020
    Revenue
    Revenue
    $27,347,642 $11,218,799
    Cost of Revenue
    18,639,793 5,401,316
    Gross profit
    8,707,849 5,817,483
    Operating expenses
    Sales and marketing
    2,848,667 1,727,469
    Distribution costs
    2,850,616 2,487,834
    General and administrative expenses
    2,255,928 2,127,846
    Share-based compensation
    421,887 927,326
    Amortization of acquired intangible assets
    1,186,821 729,909
    Depreciation
    286,084 194,497
    9,850,003 8,194,881
    Loss from operations
    (1,142,154) (2,377,398)
    Other expense (income), net
    Change in derivative liability
    - (1,770)
    Interest expense, net
    874,185 433,478
    Other expense (income), net
    874,185 431,708
    Loss from operations before income tax
    (2,016,339) (2,809,106)
    Gain (Loss) from the sale of Interactive Offers
    380,624 -
    (Loss) income from discontinued operations
    (193,040) (644,615)
    Income tax benefit
    472,367 708,201
    Net loss
    (1,356,388) (2,745,520)
    Net loss attributable to noncontrolling interest
    - 148,005
    Net loss attributable to Upexi, Inc.
    $(1,356,388) $(2,597,515)
    Basic and Diluted loss per share:
    (Loss) per share from continuing operations
    $(0.07) $(0.16)
    (Loss) per share from discontinued operations
    $(0.01) $(0.04)
    Total loss per share
    $(0.07) $(0.16)
    Basic weighted average shares outstanding
    20,244,618 16,713,345
    Fully diluted weighted average shares outstanding
    20,244,618 16,713,345

    SOURCE: Upexi, Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/807311/upexi-revenue-increases-144-year-over-year-and-535-sequentially-to-273-million-for-fiscal-first-quarter-2024

    Get the next $UPXI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $UPXI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $UPXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Marshall Allan bought $1,500,001 worth of shares (657,895 units at $2.28) and was granted 75,000 shares, increasing direct ownership by 484% to 884,318 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:36 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Director Williams Thomas Charles

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:45 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Norstrud Andrew James bought $100,001 worth of shares (43,860 units at $2.28) and was granted 100,000 shares, increasing direct ownership by 942% to 159,138 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:26 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BitGo and Upexi Announce Strategic Partnership to Secure Digital Asset Treasury Holdings

      BitGo, the leading infrastructure provider of digital asset solutions, today announced a strategic partnership with Upexi Inc. (NASDAQ:UPXI), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space. Under this partnership, Upexi will leverage BitGo's secure custodial and over-the-counter (OTC) trading services to manage its growing digital asset portfolio. This move builds on Upexi's recent announcement that it has increased its Solana (SOL) treasury holdings to over 595,000 tokens, valued at approximately $100 million at current value, and has begun generating staking revenue as part of its broad

      5/13/25 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Regains Compliance with NASDAQ

      Filing Form 10-K for the Year Ended June 30, 2024Filing Form 10-Q for the Quarter Ending September 30, 2024 TAMPA, FL / ACCESSWIRE / December 23, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products, announced its financial results for the year ended June 30, 2024 and the first quarter ending September 30, 2024 last week. On November 20, 2024 the Company received written notice (the "Compliance Notice") from Nasdaq informing the Company that it has regained compliance with Nasdaq Listing Rule 5250( c)(1) (the "Rule"). The Staff had concluded that with the filing of these two periodic re

      12/23/24 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mangoceuticals, Inc. Initiates Investigation into Potential Stock Manipulation Scheme Following Recent Reverse Stock Split

      DALLAS, TX, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, today announced that it has launched an investigation into potential stock manipulation related to and following its recent reverse stock split, which was effective as of October 16, 2024. This decision follows a comprehensive review of highly irregular trading patterns and an unprecedented increase in the number of shareholder accounts, factors that collectively raise concerns about potential stock manipulation. This investigation also follows a recent r

      12/4/24 7:00:00 AM ET
      $MGRX
      $UPXI
      Misc Health and Biotechnology Services
      Health Care
      Medicinal Chemicals and Botanical Products

    $UPXI
    SEC Filings

    See more
    • Upexi Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - UPEXI, INC. (0001775194) (Filer)

      5/23/25 5:00:13 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form S-1 filed by Upexi Inc.

      S-1 - UPEXI, INC. (0001775194) (Filer)

      5/22/25 5:04:41 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - UPEXI, INC. (0001775194) (Filer)

      5/16/25 5:00:13 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    Financials

    Live finance-specific insights

    See more
    • Upexi Regains Compliance with NASDAQ

      Filing Form 10-K for the Year Ended June 30, 2024Filing Form 10-Q for the Quarter Ending September 30, 2024 TAMPA, FL / ACCESSWIRE / December 23, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products, announced its financial results for the year ended June 30, 2024 and the first quarter ending September 30, 2024 last week. On November 20, 2024 the Company received written notice (the "Compliance Notice") from Nasdaq informing the Company that it has regained compliance with Nasdaq Listing Rule 5250( c)(1) (the "Rule"). The Staff had concluded that with the filing of these two periodic re

      12/23/24 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Reports Fiscal Second Quarter 2024 Financial Results

      TAMPA, FL / ACCESSWIRE / February 14, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct to Consumer brand owner and innovator in aggregation, today reported its financial results for the fiscal second quarter 2024 ending December 31, 2023."During the quarter we continued to focus on optimizing and streamlining our operations, investing in our higher margin Brand Products and generating positive Adjusted EBITDA. While revenue for the most recent fiscal second quarter decreased sequentially, the operating measures we took allowed us to increase gross profit margins to 38%, as compared to the prior fiscal first quarter of 31.8%. We also generated pos

      2/14/24 4:05:00 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi to Host Fiscal 2024 Second Quarter Financial Results Conference Call on February 14th at 4:30 PM ET

      TAMPA, FL / ACCESSWIRE / February 12, 2024 / Upexi Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct-to-Consumer brand owner and innovator in aggregation, today announced it will host a conference call on Wednesday, February 14, 2024 at 4:30 p.m. ET, to discuss its financial results for the fiscal 2024 second quarter and provide a business update.Financial Results Conference CallEvent:Fiscal 2024 Second Quarter Financial Results Conference CallDate:Wednesday, February 14, 2024Time:4:30 p.m. Eastern TimeLive Call:1-877-407-9716 (U.S. Toll Free) or 1-201-493-6779 (International)Webcast:https://ir.upexi.com/news-events/ir-calendarFor those unable to join the confe

      2/12/24 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Upexi Inc.

      SC 13G - UPEXI, INC. (0001775194) (Subject)

      5/31/23 7:05:10 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Upexi Inc.

      SC 13G - UPEXI, INC. (0001775194) (Subject)

      3/10/23 4:37:37 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Upexi Inc. (Amendment)

      SC 13G/A - UPEXI, INC. (0001775194) (Subject)

      3/10/23 4:36:56 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Marshall Allan bought $1,500,001 worth of shares (657,895 units at $2.28) and was granted 75,000 shares, increasing direct ownership by 484% to 884,318 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:36 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Norstrud Andrew James bought $100,001 worth of shares (43,860 units at $2.28) and was granted 100,000 shares, increasing direct ownership by 942% to 159,138 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:26 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Salkind Gene bought $550,002 worth of shares (241,229 units at $2.28), increasing direct ownership by 195% to 365,127 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:17 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care